International IP Arbitration - A Blessing or a Bad Idea?

October 2019

Summary

Medtech companies traditionally resolved disputes over IP rights before national courts, but more and more of them are now turning to international arbitration to protect their IP rights. Dorothee Schramm explains the benefits of this growing trend and the pitfalls to avoid.

Authors: Dorothee Schramm

View Article

Contacts

Dorothee Schramm

Partner

dschramm@sidley.com +41 22 308 0038

Geneva

Related Capabilities

SERVICES

Global Arbitration, Trade and Advocacy
EU - Food, Drug and Medical Device Regulatory

INDUSTRIES

Global Life Sciences

Offices

Geneva

Suggested News & Insights

Stay Up To Date

Subscribe to

Sidley Publications

Client Login Attorney Advertising Privacy Policy Terms & Conditions Contact Us Social Media Directory

Locations

Site Language Updated

Select Your Edition and Language Preference

Global

English

Asia Pacific

English 中文日本語

Europe

English

United States

English

We use cookies on our website. To learn more about cookies, how we use them on our site and how to revise your cookie settings please view our cookie policy.

You have successfully set your edition to United States. Would you like to make this selection your default edition?

*Selecting a default edition will set a cookie.

This page is available in your default region.

Cookies Notice

We use cookies on our website. To learn more about cookies, how we use them on our site and how to revise your cookie settings please view our cookie policy.

Necessary Cookies

Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences. To learn more about cookies, how we use them on our site and how to revise your cookie settings, please view our updated privacy and cookie policy.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage.